NCT01424982 2026-04-15
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
58 trialsNCT04978584 2026-04-15
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05922904 2026-04-15
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00092222 2026-04-14
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT00792948 2026-04-13
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03269669 2026-04-13
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03786783 2026-04-13
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04739800 2026-04-13
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05303792 2026-04-07
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT05467670 2026-03-04
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
University of Pittsburgh
Phase 2 Active not recruiting
NCT01946529 2026-02-23
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03755804 2026-02-23
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03407144 2026-02-19
MK-3475-667
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT05137262 2026-02-18
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04980222 2026-02-17
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03710772 2026-02-11
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03749018 2026-02-06
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02876302 2026-02-04
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03943901 2026-01-29
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT03587662 2026-01-09
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06425302 2026-01-08
GOLSEEK-2
Celgene
Phase 2 Active not recruiting
NCT01025089 2026-01-07
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT01871766 2025-12-17
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT04594798 2025-12-17
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
University of Rochester
Phase 2 Active not recruiting
NCT01920932 2025-12-03
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02623972 2025-11-25
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02427620 2025-11-21
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01750073 2025-11-18
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT03113500 2025-11-14
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00077285 2025-11-04
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04443348 2025-10-14
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04479267 2025-09-29
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Active not recruiting
NCT00295893 2025-09-25
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03004287 2025-09-10
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
Phase 2 Active not recruiting
NCT04243616 2025-09-05
CemiHALT
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT02957968 2025-08-28
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
Phase 2 Active not recruiting
NCT03505762 2025-08-20
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT02734771 2025-08-12
BV mini CHP
University of Rochester
Phase 2 Active not recruiting
NCT04546620 2025-08-06
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Phase 2 Active not recruiting
NCT05673785 2025-07-14
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Takeda
Phase 2 Active not recruiting
NCT04083963 2025-07-10
Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer
University of Illinois at Chicago
Phase 2 Active not recruiting
NCT00871013 2025-07-01
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
University of Arkansas
Phase 2 Active not recruiting
NCT00869232 2025-06-29
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Active not recruiting
NCT03995147 2025-06-08
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
University of Chicago
Phase 2 Active not recruiting
NCT01840592 2025-05-02
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03719430 2025-04-29
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
Phase 2 Active not recruiting
NCT05498896 2025-03-10
BARBICAN
Queen Mary University of London
Phase 2 Active not recruiting